DBV Technologies S.A. (NASDAQ:DBVT) Receives $35.38 Average PT from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $35.3750.

DBVT has been the subject of a number of recent research reports. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a report on Thursday, December 18th. Finally, Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th.

DBV Technologies Trading Up 0.7%

Shares of NASDAQ:DBVT opened at $19.06 on Friday. The company has a market capitalization of $765.25 million, a PE ratio of -3.69 and a beta of -1.10. DBV Technologies has a 12-month low of $2.92 and a 12-month high of $26.18. The business’s fifty day simple moving average is $15.63 and its 200-day simple moving average is $12.13.

Insider Transactions at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. This represents a 19.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.44% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nan Fung Trinity HK Ltd. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $340,000. Vivo Capital LLC purchased a new stake in DBV Technologies during the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies in the second quarter valued at about $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies in the second quarter valued at about $9,659,000. Finally, Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies in the second quarter worth about $9,315,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.